Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linagliptin add-on to empagliflozin and metformin in type 2 diabetes
2012-002271-34Phase 3Completed
- Sponsor
- Unilfarma
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of linagliptin and empagliflozin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Unilfarma. Primary endpoint: Change in HbA1c from baseline at 24 weeks. Started Oct 2012; status: completed.
02
Drugs
linagliptinempagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2012-002271-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002271-34.